Year: 2025

BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of its novel BCL2 inhibitor, Mesutoclax (ICP-248), were presented at the 67th Annual Meeting of the American Society of Hematology (ASH). Mesutoclax demonstrated remarkable efficacy and a favorable safety profile in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and acute myeloid leukemia (AML). The study of mesutoclax in the treatment of relapsed/refractory MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster presentations. Oral Presentation Title: Efficacy and tolerability of mesutoclax...

BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) — Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, announced today the grant of an inducement restricted stock award of 1,000,000 shares of common stock (“Restricted Stock Award”) to a new employee under the Netcapital Inc. 2023 Omnibus Equity Incentive Plan (the “Plan”). The Restricted Stock Award was granted as an inducement under the Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Equity Incentive Plan provides for the issuance of equity awards in the form of inducement grants pursuant to Nasdaq Listing Rule 5635(c). The Restricted Stock Award will have voting rights upon issuance and will vest, in whole or in part, on March 15, 2027, with the number of shares of...

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy  Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy data support potential advancement to earlier treatment lines for a broader patient populationROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the latest data on Olverembatinib, the Company’s novel drug, in second-line treatment of patients with chronic myeloid leukemia...

By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectively High-risk IKZF1plus patients showed 90% molecular response rate Low-intensity chemotherapy combination achieved deep responses with favorable safety profileROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the first dataset from the global registrational Phase III study (POLARIS-1) of the company’s novel, investigational drug, Olverembatinib...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival)ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented four year follow-up data from its randomized controlled, registrational Phase II study of Olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase...

Zwerling expected to guide the Company to its commercial launch APOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, combined with advanced genetic testing, today announced the signing of an agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026. Mr. Zwerling brings more than three decades of global experience in healthcare, finance, and operations across pharmaceuticals, medical imaging, biotechnology, and digital health. “As the Company prepares for commercialization, RetinalGenix requires a financial, strategic, and operational leader who understands regulated medical devices, clinical development, reimbursement...

Return Marks Full-Circle Moment for Scenebot Stage Discovery LOS ANGELES, Dec. 08, 2025 (GLOBE NEWSWIRE) — Stargaze Entertainment Group Inc. (“Stargaze” or the “Company”) (OTCQB: STGZ), a next-generation content creation and social platform designed to redefine talent discovery, proudly announces that acclaimed Broadway performer Morgan Dudley has joined the Company as a Creative Advisor. Dudley, currently starring on Broadway in the Tony Award-winning musical Hadestown, first emerged from the original Scenebot Stage platform—Stargaze’s earlier incarnation—which launched her path to professional representation in 2019. Her talent was quickly recognized, leading to starring roles in Broadway’s Jagged Little Pill and Disney’s Descendants: The Rise of Red. Now, as the newly updated Stargaze platform prepares for its relaunch, Dudley...

TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer’s Disease (AD) treatment in China. The Commercial Insurance Innovative Drug List is based on new policies of the Chinese government to support the development and access of innovative medicines....

SecureTech Backing Enables AI UltraProd’s U.S. Accessory Dwelling Unit Beachhead; 2026 Rollout and Expansion Strategy Roseville, Minnesota, Dec. 08, 2025 (GLOBE NEWSWIRE) — AI UltraProd, Inc. (“Ai UltraProd”, AIUP”, or “the Company”), a global leader in AI-driven industrial solutions specializing in robotic 3D printing and advanced intelligent manufacturing systems, and a wholly owned subsidiary of SecureTech Innovations, Inc. (“SecureTech”) (OTCQB: SCTH), today announced its official entry into the United States market, beginning with a focused strategy centered on the rapidly expanding Accessory Dwelling Unit (ADU) sector. The decision follows extensive market analysis, emerging regulatory alignment, and growing nationwide demand for faster, more sustainable, and more affordable residential construction...